A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.

@article{Ilson2011AP2,
  title={A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.},
  author={David H. Ilson and David K Kelsen and Manish Shah and Gary K. Schwartz and Douglas A. Levine and Jeff Boyd and Marinela Capanu and Benjamin Miron and David Klimstra},
  journal={Cancer},
  year={2011},
  volume={117 7},
  pages={1409-14}
}
BACKGROUND Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated esophageal cancer. METHODS Thirty patients with measurable, metastatic cancer of the esophageal and gastroesophageal junction received 150 mg erlotinib daily. EGFR-negative tumors (6 patients; 20%) and EGFR-over expressing tumors (24 patients; 80%) were treated. Most patients were men… CONTINUE READING